Ингарон®

General characteristics. Structure:

Active ingredient: 100000 ME, 500000 ME, 1000000 ME, 2000000 ME interferon scale.

Excipients: mannitol (Mannitolum), sodium chloride, sodium phosphate monosubstituted, sodium phosphate disubstituted.

Pharmacological properties:

Pharmacodynamics. Ингарон® - recombinant interferon scale of the person, consists of 144 amino-acid remains (а.о.), it is deprived of the first three а.о. Cys-Tyr-Cys replaced with Met. Molecular weight is 16,9 kd. Interferon scale is the major immune cytokine which producers in a human body are many cells among which there are NK cells, Th1 CD4 + and CD8+ T lymphocytes. To interferon scale macrophages, neutrophils, NK cells and cytotoxic T lymphocytes have receptors. Unlike other interferon raises an expression of GKGS antigens as I and II classes, thereby promoting increase in efficiency of the presentation of antigens and their recognition by T lymphocytes.

Interferon scale has the following properties:

- Activates immunocompetent cages in particular: their mikrobotsidnost, cytotoxicity, products of cytokines, superoxidic and nitrooxidic radicals, causing death of intracellular parasites, strengthens products of proteins of an acute phase of an inflammation (C2 and C4 of components of system of a complement).

- Inhibits the V-cellular answer and suppresses products of IgE.

- Is the inductor of apoptosis of V-cells, originative to autoreactive clones, causing autoimmune reactions.

- Interferon scale blocks replication of virus DNA and RNA, synthesis of virus proteins and assembly of mature virus particles. Interferon scale makes cytotoxic impact on virusinfitsirovanny cells.

- Interferon scale blocks synthesis of the transforming growth factor (TGF) responsible for development of fibrosis.

Indications to use:

- Treatment of a chronic viral hepatitis With, a chronic viral hepatitis In, HIV/AIDS of an infection and a pulmonary tuberculosis in complex therapy.
- Prevention of infectious complications at patients with a chronic granulematozny disease.
- Treatment of oncological diseases in complex therapy as an immunomodulator, including in a combination with chemotherapy.
- Treatment of a genital herpesviridae infection and shingles (herpes zoster) in monotherapy.
- Treatment of urogenital clamidiosis in complex therapy.
- Treatment of chronic prostatitis in complex therapy.
- Treatment of anogenitalny warts (virus of papilloma of the person) and prevention of a recurrence of a disease.

Route of administration and doses:

Administration of drug intramusculary or subcutaneously. Contents of a bottle are dissolved in 1-2 ml of water for injections. The dose of drug is established individually.

For treatment of patients with a chronic viral hepatitis In, a chronic viral hepatitis With, and also HIV/AIDS an infection and a pulmonary tuberculosis the average daily dose for adults makes 500 000 ME. 1 time a day, daily or every other day is entered. The course of treatment makes from 1 to 6 months, if necessary in 1-2 months the course of treatment is repeated.

For prevention of infectious complications at patients with a chronic granulematozny disease usually average daily dose for adults makes 500 000 ME. 1 time a day, daily or every other day is entered. Prolong for a course of 5-15 injections, if necessary a course or repeat in 10-14 days.

For treatment of oncological diseases the average daily dose for adults makes 500 000 ME. 1 time a day every other day is entered.

For treatment of a genital herpesviridae infection, shingles (herpes zoster) and urogenital clamidiosis the average daily dose for adults makes 500 000 ME. 1 time a day subcutaneously, every other day is entered. The course of treatment makes 5 injections.

For treatment of chronic prostatitis the daily dose makes 100000 ME or 500 000 ME. 1 time a day subcutaneously, every other day is entered. The course of treatment makes 10 injections.

For treatment of anogenitalny warts the daily dose makes 100 000 ME. 1 time a day subcutaneously, after the carried-out cryolysis, every other day is entered.
The course of treatment makes 5 injections.

Side effects:

Local morbidity in the place of an injection in the form of a mild pain of the aching character (like the overtrained muscle) and a hyperemia.

Use of high doses over 1 000 000 ME can be followed by development of a grippopodobny syndrome: headache, weakness, fervescence, joint pains.

Poorly expressed symptoms do not demand pharmacological correction. At the expressed phenomena – stopping by means of non-steroidal anti-inflammatory drugs.

Contraindications:

Individual intolerance of interferon scale or any other component of drug. Pregnancy. Autoimmune diseases. Diabetes mellitus.

Storage conditions:

To store in the dry, protected from light place, at a temperature of 2-10 °C. Not to freeze. To store in the place, unavailable to children. A period of validity - 2 years. Not to use after the expiry date specified on packaging.

Issue conditions:

According to the recipe

Packaging:

Lyophilisate for preparation of solution for intramuscular and hypodermic introduction, 100000 ME, 500000 ME, 1000000 ME, 2000000 ME. On 100 000 ME, 500000 ME, 1000000 ME or 2000000 ME drugs in FI bottles from glass with a capacity of 3 ml. Bottles are hermetically corked by medical rubber bungs and rolled by caps aluminum for corking of medicines. On 5 bottles in blister strip packagings or in cassette planimetric packagings. On 1, 2, 3 or 4 planimetric packagings together with the application instruction place in a pack from a cardboard bandbox.